Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
Mobius Mobility has been recognized by MedTech Outlook Magazine as the exclusive recipient of “Top 10 Mobility Aids Companies - 2022 ,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the MedTech Outlook research and editorial team based on insights from an interview with Dean Kamen, Inventor of iBOT®PMD.
Dean Kamen, Inventor of iBOT®PMD
Company
Mobius Mobility
Management
Dean Kamen, Inventor of iBOT®PMD and Megan Yeigh, Program Manager
Description
Mobius Mobility offers iBOT Personal Mobility Device (iBOT®PMD), a revolutionary multi-modal powered wheelchair with all-terrain capabilities that is putting an end to many long-standing mobility-related issues faced by people with disabilities. Embedded with terrain-following technology, the iBOT® PMD’s four-wheel mode performs like a quieter, smarter cousin of an ATV, engaging all of its large drive wheels while automatically keeping the seat level. iBOT® PMD’s patented balancing technology provides a never-before-felt mobility experience. The fully redesigned iBOT®PMD also comes with configurable rehab seating features to customize a variety of backrests, armrests, and footrests—tailored to the specific needs of each particular user.
Sito Web:
mythras.it
Amministratore:
Roberto Livio Mastronardi, co-fondatore
Descrizione:
Mythras è un team di tecnici specializzati nell'assistenza tecnica su strumentazione IVD, esperti nell'aiutare i responsabili di laboratorio a garantire la precisione, l'accuratezza e la conformità dei loro strumenti. È la scelta ideale per numerosi clienti e distributori, al servizio delle loro complesse esigenze di assistenza tecnica e ricondizionamento della strumentazione IVD.
Citazione:
“Siamo certificati ISO 9001:2015 per l'assistenza tecnica e il ricondizionamento della strumentazione analitica IVD.”
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
